Kevin D. Bunting, PhD
Associate Professor of Medicine
EDUCATION
1987-1991 Pfeiffer College, Misenheimer, North Carolina
B.S., Biology / Chemistry minor (GPA 3.8 out of 4.0)
1991-1995 Wake Forest University, Winston-Salem, North Carolina
Ph.D., Biochemistry (GPA 2.73 out of 3.0)
POST GRADUATE EDUCATION AND TRAINING
1991 Lab Technician (summer) and graduate student rotation with
Dr. Daniel J. Fernandes, Biochemistry Dept., Wake Forest University,
Winston Salem, North Carolina
1992-1995 Graduate studies with Dr. Alan J. Townsend, Biochemistry
Dept.,
Wake Forest University, Winston-Salem, North Carolina.
1995-1999 Postdoctoral fellow with Dr. Brian P. Sorrentino,
Division of Experimental Hematology, St. Jude Children's Research
Hospital, Memphis, Tennessee.
PROFESSIONAL APPOINTMENTS
1999-2004 Scientist I (Assistant Professor Equivalent), Hematopoiesis
Department, American Red Cross Holland Laboratory, Rockville,
Maryland.
2000-2004 Assistant Professor, Department of Anatomy and Cell
Biology, George Washington University Medical Center, Washington,
D.C.
2000-2004 Member, the George Washington University Institute
for the Biomedical Sciences (GWIBS) Genetics Program
2004-present Associate Professor, tenure-track, Department of
Medicine, Division of Hematology/Oncology, Case Western Reserve
University, Cleveland, OH (Primary)
2004-present Associate Professor, tenure-track, Department of
Medicine, Division of General Medical Sciences, Cancer Center,
Cleveland, OH (Secondary)
2005-present Associate Professor, tenure-track, Department of
Pathology, Case, Cleveland, OH (Secondary)
PROFESSIONAL MEMBERSHIPS
1993-present American Association for Cancer Research
1996-present American Association for the Advancement of Science
1996-present American Society of Hematology
1997-2007 American Society of Gene Therapy
2001-present New York Academy of Sciences
2003-present International Society for Stem Cell Research
HONORS AND AWARDS
1994 Camillo and Bianca Artom Fellowship for achievement in
research, Biochemistry Dept., Wake Forest University.
1994 Bristol-Meyers Oncology Travel Award to attend the 1994
American Association for Cancer Research (AACR) meeting in San
Francisco, CA.
1995 AACR Travel Award to attend the 1995 AACR meeting in Toronto,
Ontario, Canada.
1998 American Society of Gene Therapy Young Investigator Travel
Award to attend the 1998 meeting in Seattle, WA.
1998 Institutional National Research Service Award (NRSA), National
Institutes of Health, National Cancer Institute (CA009346-19),
St. Jude Children’s Research Hospital, Training in the
Biology of Cancer.
2004 National Institutes of Health, Office of International
Affairs, NCI Oncology Research Faculty Development Program,
$37,100 to support Yi Zhang.
Journals (Refereed)
1. Bunting KD, Lindahl R, Townsend AJ. Oxazaphosphorine-specific
resistance in
human MCF-7 breast carcinoma cell lines expressing transfected
rat class 3 aldehyde dehydrogenase. J Biol Chem 269: 23197-23203,
1994.
2. Bunting KD, Townsend AJ. De novo expression of transfected
human class-1 aldehyde dehydrogenase causes resistance to oxazaphosphorine
anticancer agents in hamster V79 cell lines. J Biol Chem 271:11884-11890,
1996.
3. Bunting KD, Townsend AJ. Protection by transfected rat or
human class 3 aldehyde dehydrogenases against the cytotoxic
effects of the oxazaphosphorine alkylating agents in hamster
V79 cell lines. J Biol Chem 271:11891-11896, 1996.
4. Bunting KD, Webb M, Giorgianni F, Galipeau J, Blakely RL,
Townsend AJ, Sorrentino BP. Coding region-specific destabilization
of mRNA transcripts attenuates expression from retroviral vectors
containing class 1 aldehyde dehydrogenase cDNAs. Hum Gene Ther
8:1531-1543, 1997.
5. Bunting KD, Sangster MY, Ihle, JN, Sorrentino, BP. Restoration
of lymphocyte function in janus kinase 3-deficient mice by retroviral-mediated
gene transfer. Nat Med 4, 58-64, 1998.
6. Bunting KD, Townsend AJ. Dependence of aldehyde dehydrogenase-mediated
oxazaphosphorine resistance on soluble thiols: Importance of
thiol interactions
with the secondary metabolite acrolein. Biochem Pharm 56, 31-39,
1998.
7. Bunting, KD, Galipeau, J, Topham, D, Benaim, E, Sorrentino,
BP. Transduction
of murine bone marrow cells with an MDR1 vector enables ex vivo
stem cell expansion, but these expanded grafts cause a myeloproliferative
syndrome in transplanted mice. Blood 92, 2269-2279, 1998.
8. Bunting KD, Flynn KJ, Riberdy JM, Dohorty PC, Sorrentino
BP. Virus-specific immunity after gene therapy in a murine model
for severe combined immunodeficiency. Proc Natl Acad Sci USA
96, 232-237, 1999.
Morrigl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, Hoffmeyer
A, van Deursen J, Sangster MY, Bunting KD, Grosveld GC, Ihle
JN. Stat5 is required for IL-2 induced cell cycle progression
of peripheral T cells. Immunity 10, 249-259, 1999.
Bunting KD, Zhou S, Lu T, Sorrentino BP. Enforced P-glycoprotein
pump function in murine bone marrow cells results in expansion
of SP cells in vitro and repopulating cells in vivo. Blood,
96, 902-909, 2000.
Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD,
Rothammer K, Roussel MF, Ihle JN. STAT5a/b contribute to IL-7
induced B cell precursor expansion, but Abl and Bcr-abl induced
transformation are independent of STAT5. Blood, 96, 2277-2283,
2000.
Bunting KD, Lu T, Kelly PF, Sorrentino BP. Self-selection by
genetically modified committed lymphocyte precursors reverses
the phenotype of JAK3-deficient mice without myeloablation.
Hum Gene Ther, 11, 2353-2364, 2000.
Wen Renren W, Wang D, McKay C, Bunting KD, Marine J, Vanin
EF, Zambetti GP, Korsmeyer SJ, Ihle JN, Cleveland JL. Jak3 selectively
regulates Bax and Bcl-2 expression to promote T cell development.
Mol Cell Biol, 21, 678-689, 2001.
Zhou S, Schuetz JD, Bunting KD, Colapietro A, Sampath J, Morris
JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino
BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety
of stem cells and is a molecular determinant of the side-population
phenotype. Nat Med, 7, 1028-1034, 2001.
Bunting KD, Bradley HL, Hawley TS, Moriggl R, Sorrentino BP,
Ihle JN. Reduced lympho-myeloid repopulating activity from adult
bone marrow and fetal liver of mice lacking expression of STAT5.
Blood, 99, 479-487, 2002.
Bunting KD. ABC transporters as phenotypic markers and functional
regulators of stem cells. Stem Cells, 20, 11-20, 2002. [Review]
Bradley HL, Hawley TS, Bunting KD. Cell intrinsic defects in
cytokine responsiveness of STAT5-deficient hematopoietic stem
cells. Blood, 100, 3983-3989, 2002.
Bunting KD, Hawley RG. The tao of hematopoietic stem cells.
Toward a unified theory of tissue regeneration? ScientificWorldJOURNAL,
2, 983-995, 2002. [Review]
Shelburne CP, McCoy ME, Piekorz R, Sexl VV, Roh K, Jacobs-Helber
SM, Gillespie SR, Bailey DP, Mirmonsef P, Mann MN, Kashyap M,
Wright HV, Chong HJ, Bouton A, Barnstein B, Ramirez CD, Bunting
KD, Sawyer S, Lantz CS, Ryan JJ. Stat5 expression is required
for mast cell development and survival. Blood, 102, 1290-1297,
2003.
Bunting KD, Hawley RG. Integrative molecular and developmental
biology of adult stem cells. Biology of the Cell, 95, 563-578,
2003. [Review]
Bradley HL, Couldrey C, Bunting KD. Hematopoietic repopulating
defects from STAT5-deficient bone marrow are not fully accounted
for by loss of thrombopoietin responsiveness. Blood, 103, 2965-2972,
2004.
Chen J, Yu WM, Bunting KD, Qu CK. A negative role of SHP-2
tyrosine phosphatase in growth factor dependent hematopoietic
cell survival. Oncogene, 23, 3659-3669, 2004.
Bunting KD, Yu WM, Bradley HL, Haviernikova E, Kelly-Welch
AE, Keegan AD, Qu CK. Increased numbers of committed myeloid
progenitors but not primitive hematopoietic stem/progenitors
in mice lacking STAT6 expression. J Leukoc Biol, 76, 484-490,
2004.
Zhu Y, Chen L, Huang Z, Alkan S, Bunting KD, Wang D, Huang
H. IL-5 primes Th2 cytokine-producing capacity in eosinophils
through a STAT5-dependent mechanism. J Immunol, 173, 2918-2922,
2004.
Haviernik P, Bunting KD. Safety concerns related to hematopoietic
stem cell gene transfer using retroviral vectors. Current Gene
Therapy, 4, 263-276, 2004. [Review]
Haviernik P, Lahoda C, Bradley HL, Hawley TS, Ramezani A, Hawley
RG, Stetler-Stevenson M, Stetler-Stevenson WG, Bunting KD. Tissue
inhibitor of matrix metalloproteinase-1 overexpression in M1
myeloblasts impairs IL-6 induced differentiation. Oncogene,
23, 9212-9219, 2004.
Couldrey C, Bradley HL, Bunting KD. A STAT5 modifier locus
on murine chromosome 7 modulates engraftment of hematopoietic
stem cells during steady-state hematopoiesis. Blood, 105, 1476-1483,
2005.
Moriggl R, Sexl V, Kenner L, Duntsch C, Stangl K, Gingras S,
Hoffmeyer A, Bauer A, Piekorz R, Wang D, Bunting KD, Wagner
EF, Sonneck K, Valent P, Ihle JN, Beug H. Stat5 tetramer formation
is associated with leukemogenesis. Cancer Cell, 7, 87-99, 2005.
Modlich U, Kustikova O, Rudolph C, Meyer J, Kamino K, v. Neuhoff
N, Li Z, Kuehlke K, Bunting KD, Schlegelberger B, Fehse B, von
Kalle C, Baum C. Insertional leukemogenesis with combinatorial
proto-oncogene hits following dose-escalated retroviral vector
transfer into murine hematopoietic cells. Blood, 105, 4235-4246,
2005.
Xu B, Haviernik P, Wolfraim LA, Bunting KD, Scott DW. Bone
marrow transplantation combined with gene therapy to induce
antigen-specific tolerance and ameliorate EAE. Molecular Therapy,
13, 42-48, 2006.
Yu WM, Daino H, Chen J, Bunting KD, Qu CK. Effects of a leukemia-associated
gain-of-function mutation of SHP-2 phosphatase on IL-3 signaling.
J Biol Chem, 281, 5426-5434, 2006.
Barnstein BO, Li G, Kennedy S, Chalfant C, Nakajima H, Wang
Z, Bunting KD, Ryan JJ. Stat5 expression is required for IgE-mediated
mast cell function. J Immunol, 177, 3421-3426, 2006.
Eckardt S, Leu NA, Bradley HL, Kato H, Bunting KD, McLaughlin
KJ. Hematopoietic reconstitution with androgenetic and gynogenetic
stem cells. Genes and Dev, 21, 409-419, 2007.
Bunting KD. STAT5 signaling in normal and pathologic hematopoiesis.
Front Biosci., 12, 2807-2820, 2007. [Review]
Zhang Y, Diaz-Flores E, Li G, Wang Z, Kang Z, Haviernikova
E, Rowe S, Qu CK, Tse W, Shannon KM, Bunting KD. Abnormal hematopoiesis
in Gab2 mutant mice. Blood, 110, 116-124, 2007.
Dai X, Chen Y, Di L, Podd A, Li G, Bunting KD, Hennighausen
L, Wen R, Wang D. Stat5 is essential for early B cell development
but not for B cell maturation and function. J Immunol, 179,
1068-1079, 2007.
Soebiyanto RP, Sreenath SN, Qu CK, Loparo KA, Bunting KD. Complex
systems biology approach to understanding coordination of JAK-STAT
signaling. Biosystems, In Press, 2007.
Chen Y, Haviernik P, Bunting KD, Yang YC. Cited2 is required
for normal hematopoiesis in the murine fetal liver. Blood, In
Press, 2007.
Li G, Wang Z, Zhang Y, Kang Z, Haviernikova E, Cui Y, Hennighausen
L, Moriggl R, Wang D, Tse W, Bunting KD. STAT5 requires the
N-domain to maintain hematopoietic stem cell repopulating function
and appropriate lymphoid-myeloid lineage output. Exp Hematol,
In Press, 2007.
Books and book chapters
1. Couldrey C, Bunting KD. (Chapter) Signal transduction in
hematopoietic stem cells. Erik V. Greer (Editor). Focus on Stem
Cell Research. Nova Science Publishers Inc., Nova Biomedical
Books, 143-190, 2004.
2. Bunting KD, (Editor). 2nd edition of Hematopoietic Stem
Cell Protocols, Methods in Molecular Biology Series, Humana
Press Publishers, In Press, early 2008.
3. Tse W, Bunting KD. (Chapter) The expanding tool kit for
hematopoietic stem cell research. Methods Mol Biol, In Press,
early 2008.
4. Wang Z, Bunting KD. (Chapter) Hematopoietic stem cell transplant
into non-myeloablated W/Wv mice to detect steady-state engraftment
defects. Methods Mol Biol, In Press, early 2008.
5. Haviernik P, Zhang Y, Bunting KD. (Chapter) Retroviral transduction
of murine hematopoietic stem cells. Methods Mol Biol, In Press,
early 2008.
Currently Funded Grants
National Institutes of Health (R01DK059380) – NIH Director’s
Bridge Award (R56DK059380)
Role: Principal Investigator (30% effort)
Title: “JAK/STAT Signaling in Hematopoietic Stem Cells”
Project Period: 03/01/02-7/31/08; Competing renewal 7.7 percentile,
pending
Direct Costs per year: $174,168
Total Grant Period Costs: $870,840
National Institutes of Health (5P30CA043703)
Role: Co-Program Leader “Stem Cells and Hematologic Malignancies”
(5% effort)
Title: “Case Comprehensive Cancer Center Support Grant”
Project Period: 09/30/91-03/30/12
National Institutes of Health (R01HL073738)
Role: Principal Investigator (30% effort)
Title: “Role of TIMPs in Hematopoietic Stem Cell Biology”
Project Period: 07/01/03-06/30/08; 1-yr no-cost extension
Direct Costs per year: $234,426
Total Grant Period Costs: $937,704
Case Western Reserve University
Center for Stem Cell and Regenerative Medicine
Stem Cell Research Initiative (SRI) Grant
Role: Principal Investigator
Title: “Pharmacologic Inhibition of STAT5 as an adjuvant
for Nonmyeloablative Bone Marrow Transplant”
Project Period: 03/01/05-02/28/08
Total Grant Period Costs: $40,000
